Genetic Assays, INC.
Genetic Assays, INC. was paid $5.15M by Medicaid between Jan 2018 and Dec 2024, across 24 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 38% of everything it billed.
NASHVILLE, TN 37220
Next to other Clinical Medical Laboratory providers in Tennessee
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 3,114 | $185K | |
| 2019 | 3,645 | $209K | |
| 2020 | 14,585 | $774K | |
| 2021 | 56,380 | $2.17M | |
| 2022 | 25,241 | $1.19M | |
| 2023 | 7,913 | $435K | |
| 2024incomplete | 4,758 | $183K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 38% | 27,014 | 23,215 | $1.96M |
| 87631 | 13% | 8,195 | 7,770 | $650K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 12% | 25,844 | 4,828 | $596K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 10% | 22,636 | 19,404 | $518K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 8.7% | 3,581 | 3,288 | $447K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 3.2% | 742 | 702 | $166K |
| 0100U | 2.7% | 516 | 496 | $139K | |
| 87486 | 2.1% | 6,577 | 5,903 | $110K | |
| 87581 | 2.1% | 6,577 | 5,903 | $110K | |
| 87507 | 2.0% | 486 | 464 | $105K | |
| 0099U | 1.1% | 201 | 197 | $57K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.0% | 1,538 | 1,466 | $54K |
12 more codes
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,526 | $50K |
| 87503 | <1% | 4,578 | $44K | |
| 87634 | <1% | 1,526 | $38K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,200 | $37K |
| 87498 | <1% | 1,532 | $19K | |
| 87506 | <1% | 190 | $16K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 130 | $10K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 305 | $5K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 311 | $5K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 311 | $5K |
| 87493 | <1% | 84 | $4K | |
| 87529 | <1% | 36 | $603.42 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.